The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
Open accessAbstract
BACKGROUND: Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in this clinical context. METHODS: Using an observational database from 169 hospitals in Asia, Europe, and North America, we evaluated the relationship of cardiovascular disease and drug therapy with in-hospital death among hospitalized patients with Covid-19 who were admitted between December 20, 2019, and March 15, 2020, and were recorded in the Surgical Outcomes Collaborative registry as having either died in the hospital or survived to discharge as of March 28, 2020. RESULTS: Of the 8910 patients with Covid-19 for whom discharge status was available at the time of the analysis, a total of 515 died in the hospital (5.8%) and 8395 survived to discharge. The factors we found to be independently associated with an increased risk of in-hospital death were an age greater than 65 years (mortality of 10.0%, vs. 4.9% among those ≤65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41), coronary artery disease (10.2%, vs. 5.2% among those without disease; odds ratio, 2.70; 95% CI, 2.08 to 3.51), heart failure (15.3%, vs. 5.6% among those without heart failure; odds ratio, 2.48; 95% CI, 1.62 to 3.79), cardiac arrhythmia (11.5%, vs. 5.6% among those without arrhythmia; odds ratio, 1.95; 95% CI, 1.33 to 2.86), chronic obstructive pulmonary disease (14.2%, vs. 5.6% among those without disease; odds ratio, 2.96; 95% CI, 2.00 to 4.40), and current smoking (9.4%, vs. 5.6% among former smokers or nonsmokers; odds ratio, 1.79; 95% CI, 1.29 to 2.47). No increased risk of in-hospital death was found to be associated with the use of ACE inhibitors (2.1% vs. 6.1%; odds ratio, 0.33; 95% CI, 0.20 to 0.54) or the use of ARBs (6.8% vs. 5.7%; odds ratio, 1.23; 95% CI, 0.87 to 1.74). CONCLUSIONS: Our study confirmed previous observations suggesting that underlying cardiovascular disease is associated with an increased risk of in-hospital death among patients hospitalized with Covid-19. Our results did not confirm previous concerns regarding a potential harmful association of ACE inhibitors or ARBs with in-hospital death in this clinical context. (Funded by the William Harvey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women's Hospital.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Sex differences in immune responses
Klein, S. L., & Flanagan, K. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.90 · Cited by 6,370
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China
Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., Gong, W., Liu, X., Liang, J., Zhao, Q., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0950 · Cited by 4,349
Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19)
Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., Wang, H., Wan, J., Wang, X., & Lu, Z. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1017 · Cited by 4,194
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Fang, L., Karakiulakis, G., & Roth, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30116-8 · Cited by 2,911
Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State
Arentz, M., Yim, E., Klaff, L., Lokhandwala, S., Riedo, F. X., Chong, M., & Lee, M. (2020) · JAMA · doi:10.1001/jama.2020.4326 · Cited by 2,259
COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
Siddiqi, H. K., & Mehra, M. R. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.03.012 · Cited by 1,701
Self-citationFerrario, C. M., Jessup, J., Chappell, M. C., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Diz, D. I., & Gallagher, P. E. (2005) · Circulation · doi:10.1161/circulationaha.104.510461 · Cited by 1,565
World Health Organization (2020) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2020.0003 · Cited by 1,329
Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection
Channappanavar, R., Fett, C., Mack, M., Ten Eyck, P. P., Meyerholz, D. K., & Perlman, S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601896 · Cited by 871
RICE, G. I., THOMAS, D. A., GRANT, P. J., TURNER, A. J., & HOOPER, N. M. (2004) · Biochemical Journal · doi:10.1042/bj20040634 · Cited by 619
Li, X. C., Zhang, J., & Zhuo, J. L. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.06.005 · Cited by 435
Do Men Have a Higher Case Fatality Rate of Severe Acute Respiratory Syndrome than Women Do?
Karlberg, J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh056 · Cited by 425
Seasonal Influenza Infections and Cardiovascular Disease Mortality
Nguyen, J. L., Yang, W., Ito, K., Matte, T. D., Shaman, J., & Kinney, P. L. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0433 · Cited by 397
Patel, A. B., & Verma, A. (2020) · JAMA · doi:10.1001/jama.2020.4812 · Cited by 378
Self-citationJoint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19
Bozkurt, B., Kovacs, R., & Harrington, B. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.04.013 · Cited by 355
Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts
Nicin, L., Abplanalp, W. T., Mellentin, H., Kattih, B., Tombor, L., John, D., Schmitto, J. D., Heineke, J., Emrich, F., Arsalan, M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa311 · Cited by 289
Angiotensin Converting Enzyme 2: A Double-Edged Sword
Wang, K., Gheblawi, M., & Oudit, G. Y. (2020) · Circulation · doi:10.1161/circulationaha.120.047049 · Cited by 265
COVID-19 Illness and Heart Failure
Mehra, M. R., & Ruschitzka, F. T. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.03.004 · Cited by 150
Self-citationMorales, D. R., Conover, M. M., You, S. C., Pratt, N. L., Kostka, K., Duarte‐Salles, T., Fernández‐Bertolín, S., Aragón, M., DuVall, S. L., Lynch, K. E., et al. (2021) · PubMed · doi:10.1016/s2589-7500(20)30289-2 · Cited by 114
Wehbe, Z., Hammoud, S. H., Soudani, N., Zaraket, H., EL‐Yazbi, A. F., & Eid, A. H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00836 · Cited by 73
Lopera-Maya, E. A., van der Graaf, A., Lanting, P., van der Geest, M., Study, L. C., Fu, J., Swertz, M. A., Franke, L., Wijmenga, C., Deelen, P., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00613 · Cited by 72
Quinn, K. L., Fralick, M., Zipursky, J. S., & Stall, N. M. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.75720 · Cited by 2
Research works printed but not linked: 1
- 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
Cited by
Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31180-6 · Cited by 1,200
Self-citationRetractedWhy does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128
Dessie, Z. G., & Zewotir, T. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06536-3 · Cited by 875
Collider bias undermines our understanding of COVID-19 disease risk and severity
Griffith, G. J., Morris, T. T., Tudball, M. J., Herbert, A., Mancano, G., Pike, L., Sharp, G. C., Sterne, J., Palmer, T. M., Davey Smith, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19478-2 · Cited by 826
Izcovich, A., Ragusa, M. A., Tortosa, F., Lavena Marzio, M. A., Agnoletti, C., Bengolea, A., Ceirano, A., Espinosa, F., Saavedra, E., Sanguine, V., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0241955 · Cited by 660
Metadata
- Authors
- Mehra, M. R., Desai, S. S., Kuy, S., Henry, T. D., & Patel, A. N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-06-18
- Volume
- 382
- Issue
- 25
- Pages
- e102-e102
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3023826646
- Cited by
- 1,428
- References
- 25
- FWCI
- 40.53
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.